Education
About Us
Working with TipRanks
Follow Us
Xtant Medical Holdings (XTNT)
:XTNT
XTNT Stock Chart & Stats
$0.75
-$0.01(-2.65%)
At close: 4:00 PM EST
$0.75
-$0.01(-2.65%)
Day’s Range― - ―
52-Week Range$0.33 - $0.95
Previous CloseN/A
Volume57.26K
Average Volume (3M)184.72K
Market Cap
$103.88M
Enterprise Value$139.83M
Total Cash (Recent Filing)$10.40M
Total Debt (Recent Filing)$15.08M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding140,000,490
10 Day Avg. Volume355,541
30 Day Avg. Volume184,719
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.38
Price to Sales (P/S)0.50
P/FCF Ratio-3.70
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda12.83
Forecast
1Y Price Target
$2.00Price Target Upside166.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe planned sale of Coflex, CoFix, and OUS Business strengthens XTNT's balance sheet, sheds a non-core group of assets, and reduces debt by approximately 50%.
EarningsXTNT generated adjusted EBITDA of $4.5M and improved its cash flow from operations.
Financial PerformanceXTNT reported revenue of $33.3M, slightly ahead of BTIG/Consensus estimates, as license revenue of $5.5M boosted results.
Bears Say
Product Segment PerformanceSpinal Implants revenue decreased by 19.9% year over year, impacting overall performance.
Xtant Medical Holdings News
XTNT FAQ
What was Xtant Medical Holdings’s price range in the past 12 months?
Xtant Medical Holdings lowest stock price was $0.33 and its highest was $0.95 in the past 12 months.
What is Xtant Medical Holdings’s market cap?
Xtant Medical Holdings’s market cap is $103.88M.
When is Xtant Medical Holdings’s upcoming earnings report date?
Xtant Medical Holdings’s upcoming earnings report date is Mar 05, 2026 which is in 104 days.
How were Xtant Medical Holdings’s earnings last quarter?
Xtant Medical Holdings released its earnings results on Nov 10, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.005 by $0.015.
Is Xtant Medical Holdings overvalued?
According to Wall Street analysts Xtant Medical Holdings’s price is currently Undervalued.
Does Xtant Medical Holdings pay dividends?
Xtant Medical Holdings does not currently pay dividends.
What is Xtant Medical Holdings’s EPS estimate?
Xtant Medical Holdings’s EPS estimate is >-0.01.
How many shares outstanding does Xtant Medical Holdings have?
Xtant Medical Holdings has 140,000,490 shares outstanding.
What happened to Xtant Medical Holdings’s price movement after its last earnings report?
Xtant Medical Holdings reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xtant Medical Holdings?
Currently, no hedge funds are holding shares in XTNT
Xtant Medical Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.93%
12-Months-Change
Fundamentals
Return on Equity
3.64%
Trailing 12-Months
Asset Growth
8.27%
Trailing 12-Months
Company Description
Xtant Medical Holdings
Xtant Medical Holdings (XTNT) is a medical device company focused on the development, manufacturing, and marketing of innovative spinal and cranial surgical solutions. Operating primarily in the orthopedic and neurosurgical sectors, Xtant Medical offers a range of products, including spinal fusion devices, bone graft substitutes, and surgical instruments designed to enhance patient outcomes in complex surgical procedures. The company aims to provide high-quality, reliable products that meet the evolving needs of healthcare professionals and their patients.
XTNT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with strong revenue growth, improved margins, and successful new product launches. However, there are some challenges in hardware revenue and slower than expected growth in the biologics product family. The pending asset sale is expected to further strengthen the company's financial position.View all XTNT earnings summariesXTNT Stock 12 Month Forecast
Average Price Target
$2.00
▲(166.67% Upside)
Technical Analysis
Ownership Overview
1.98% Insiders
2.07% Mutual Funds
54.09% Other Institutional Investors
40.37% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---